Content of CD4+ cells expressing CD39/CD73 ectonucleotidases in children with inflammatory bowel diseases

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Bulletin of Russian State Medical University Pub Date : 2022-07-01 DOI:10.24075/brsmu.2022.039
T. Radygina, S. Petrichuk, D. Kuptsova, A. Potapov, AS Illarionov, AO Anushenko, O. Kurbatova, E. Semikina
{"title":"Content of CD4+ cells expressing CD39/CD73 ectonucleotidases in children with inflammatory bowel diseases","authors":"T. Radygina, S. Petrichuk, D. Kuptsova, A. Potapov, AS Illarionov, AO Anushenko, O. Kurbatova, E. Semikina","doi":"10.24075/brsmu.2022.039","DOIUrl":null,"url":null,"abstract":"The regulation of TNF inhibitor therapy-associated immune responses in inflammatory bowel diseases (IBD) in children remains an urgent problem. The study aimed at analyzing the expression of CD39/CD73 endonucleotidases by different subsets of peripheral blood T cells in children with IBD including Crohn's disease (n = 34) and ulcerative colitis (n = 33) having received TNF inhibitors in comparison with conditionally healthy children (n = 45). Lymphocyte subsets including regulatory T cells (Treg, CD4+CD127lowCD25high), activated T cells (Tact, CD4+CD25+CD127high) and Th17 cells (CD4+CD161+CD3+) were studied by flow cytometry. The results are presented as medians (Me) and quartiles (Q25–Q75). In children with IBD the highest and the lowest relative counts of CD39+ cells were found in Treg and Tact subsets — 31% (15–38) and 4% (1–7), respectively. The highest relative counts of CD73+ cells were found in Tact — 13% (8–21). The CD39 and CD73 expression ratio in patients with IBD, and in the control group as well, depended on particular subset. CD39 expression in Treg, Tact and Th17 of patients with IBD was not age-dependent. Patients with acute Crohn's disease revealed decreased expression of CD39 in Treg compared with the control group (12% (9–23) vs 35% (28–39), respectively; р = 10–6). Patients with Crohn's disease in remission revealed increased expression of CD39 in Treg compared with the acute of the disease (31% (27–40) vs 12% (9–23); р = 9.4 × 10–5). Patients with Crohn's disease in remission revealed no significant differences with the control group apart from reduced expression of CD73 by Treg in Crohn's disease. The results indicate significant association of CD39 and CD73 expression levels in particular subsets of CD4+ cells with the phase of the disease (acute vs remission) and, accordingly, with the anti-TNF regimen efficacy.","PeriodicalId":9344,"journal":{"name":"Bulletin of Russian State Medical University","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Russian State Medical University","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24075/brsmu.2022.039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

The regulation of TNF inhibitor therapy-associated immune responses in inflammatory bowel diseases (IBD) in children remains an urgent problem. The study aimed at analyzing the expression of CD39/CD73 endonucleotidases by different subsets of peripheral blood T cells in children with IBD including Crohn's disease (n = 34) and ulcerative colitis (n = 33) having received TNF inhibitors in comparison with conditionally healthy children (n = 45). Lymphocyte subsets including regulatory T cells (Treg, CD4+CD127lowCD25high), activated T cells (Tact, CD4+CD25+CD127high) and Th17 cells (CD4+CD161+CD3+) were studied by flow cytometry. The results are presented as medians (Me) and quartiles (Q25–Q75). In children with IBD the highest and the lowest relative counts of CD39+ cells were found in Treg and Tact subsets — 31% (15–38) and 4% (1–7), respectively. The highest relative counts of CD73+ cells were found in Tact — 13% (8–21). The CD39 and CD73 expression ratio in patients with IBD, and in the control group as well, depended on particular subset. CD39 expression in Treg, Tact and Th17 of patients with IBD was not age-dependent. Patients with acute Crohn's disease revealed decreased expression of CD39 in Treg compared with the control group (12% (9–23) vs 35% (28–39), respectively; р = 10–6). Patients with Crohn's disease in remission revealed increased expression of CD39 in Treg compared with the acute of the disease (31% (27–40) vs 12% (9–23); р = 9.4 × 10–5). Patients with Crohn's disease in remission revealed no significant differences with the control group apart from reduced expression of CD73 by Treg in Crohn's disease. The results indicate significant association of CD39 and CD73 expression levels in particular subsets of CD4+ cells with the phase of the disease (acute vs remission) and, accordingly, with the anti-TNF regimen efficacy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
炎症性肠病患儿表达CD39/CD73外核苷酶的CD4+细胞含量
儿童炎症性肠病(IBD)中TNF抑制剂治疗相关免疫反应的调节仍然是一个紧迫的问题。本研究旨在分析接受TNF抑制剂治疗的IBD患儿(包括克罗恩病(n = 34)和溃疡性结肠炎(n = 33))外周血T细胞不同亚群CD39/CD73内核苷酸酶的表达,并与条件健康儿童(n = 45)进行比较。淋巴细胞亚群包括调节性T细胞(Treg, CD4+CD127lowCD25high)、活化T细胞(Tact, CD4+CD25+CD127high)和Th17细胞(CD4+CD161+CD3+)。结果以中位数(Me)和四分位数(Q25-Q75)表示。在IBD患儿中,Treg和Tact亚群中CD39+细胞的相对计数最高和最低,分别为31%(15-38)和4%(1-7)。Tact中CD73+细胞的相对计数最高,为13%(8-21)。CD39和CD73在IBD患者和对照组中的表达比例取决于特定的亚群。IBD患者Treg、Tact和Th17中CD39的表达与年龄无关。与对照组相比,急性克罗恩病患者Treg中CD39的表达降低(分别为12%(9-23)和35% (28-39);= 10-6)。与克罗恩病急性期相比,缓解期克罗恩病患者Treg中CD39的表达增加(31% (27-40)vs 12% (9-23);= 9.4 × 10-5)。克罗恩病缓解期患者除了Treg在克罗恩病中CD73的表达降低外,与对照组无显著差异。结果表明,CD39和CD73在特定CD4+细胞亚群中的表达水平与疾病的阶段(急性期与缓解期)显著相关,因此也与抗tnf方案的疗效相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Bulletin of Russian State Medical University
Bulletin of Russian State Medical University MEDICINE, GENERAL & INTERNAL-
CiteScore
0.80
自引率
0.00%
发文量
59
期刊介绍: Bulletin of Russian State Medical University (Bulletin of RSMU, ISSN Print 2500–1094, ISSN Online 2542–1204) is a peer-reviewed medical journal of Pirogov Russian National Research Medical University (Moscow, Russia). The original language of the journal is Russian (Vestnik Rossiyskogo Gosudarstvennogo Meditsinskogo Universiteta, Vestnik RGMU, ISSN Print 2070–7320, ISSN Online 2070–7339). Founded in 1994, it is issued once every two months publishing articles on clinical medicine and medical and biological sciences, first of all oncology, neurobiology, allergy and immunology, medical genetics, medical microbiology and infectious diseases. Every issue is thematic. Deadlines for manuscript submission are announced in advance. The number of publications on topics in spite of the issue topic is limited. The journal accepts only original articles submitted by their authors, including articles that present methods and techniques, clinical cases and opinions. Authors must guarantee that their work has not been previously published elsewhere in whole or in part and in other languages and is not under consideration by another scientific journal. The journal publishes only one review per issue; the review is ordered by the editors.
期刊最新文献
Genetically encoded light-inducible sensor for nucleolar visualization Prefrontal cortex transcranial theta-burst stimulation frequency-dependent effects on cognitive functions Comparative bioinformatics analysis of antimicrobial resistance gene pool in the genomes of representatives of genus Corynebacterium Efficacy of the jawbone defect elimination Ischemic stroke with and without brachiocephalic artery dissections: results of comprehensive examination of patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1